Glycated Albumin Is Superior to Hemoglobin A1c for Evaluating the Presence and Severity of Coronary Artery Disease in Type 2 Diabetic PatientsShen Y.a · Pu L.J.b · Lu L.a, b · Zhang Q.a · Zhang R.Y.a · Shen W.F.a, b
aDepartment of Cardiology, Rui Jin Hospital, and bInstitute of Cardiovascular Diseases, Shanghai Jiaotong University School of Medicine, Shanghai, PR China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: This study aimed to compare the value of serum glycated albumin (GA) level versus glycated hemoglobin A1c (HbA1c) for evaluating the presence and severity of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). Methods: Serum GA and blood HbA1c levels were measured in 829 consecutive T2DM patients with or without angiographically documented significant CAD (≥70% diameter stenosis). Results: Serum GA levels were higher in diabetic patients with significant CAD than in those without (20.57 ± 4.23 vs. 19.00 ± 4.48%; p < 0.001), but HbA1c was similar in the two groups (7.74 ± 1.34 vs. 7.51 ± 1.37% p > 0.05). Compared to HbA1c, GA correlated more closely with the sum of significant stenotic lesions (r = 0.275, p < 0.001 and r = 0.092, p = 0.019) and the extent index (r = 0.375, p < 0.001 and r = 0.091, p = 0.019). The area under the curve of GA was larger than that of HbA1c for detecting the presence of significant CAD (0.637 vs. 0.568; p = 0.046) and 3-vessel disease (0.620 vs. 0.536; p = 0.039). GA, but not HbA1c, was independently associated with significant CAD. Conclusions: Serum GA level is a better indicator than HbA1c for evaluating the presence and severity of CAD and predicting major adverse cardiac events in patients with T2DM.
© 2012 S. Karger AG, Basel
- Cohen MP, Ziyadeh FN, Chen S: Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006;147:211–219.
- Lu L, Peng WH, Wang W, Wang LJ, Chen QJ, Shen WF: Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. Zhejiang Univ Sci B 2011;12:652–659.
- Shrom D, Sarwat S, Ilag L, Bloomgarden ZT: Does hemoglobin A1c consistently reflect mean plasma glucose? J Diabetes 2010;2:92–96.
- Ravipati G, Aronow WS, Ahn C, Sujata K, Saule LN, Weiss M: Association of hemoglobin A1c level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006;97:968–969.
- Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y, Hiraoka H: Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology 2010;116:51–57.
- Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, Ding FH, Chen QJ, Lou S, Shen J, Fang DH, Shen WF: Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006;5:27.
- Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF: Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009;206:540–545.
- Ai M, Otokozawa S, Schaefer EJ, Asztalos BF, Nakajima K, Shrader P, Kathiresan S, Meigs JB, Williams G, Nathan DM: Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chim Acta 2009;406:71–74.
- Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, Wada T: Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007;46:807–814.
- Ibrahim AS, El-Remessy AB, Matragoon S, Zhang W, Patel Y, Khan S, Al-Gasyyar MM, El-Shishtawy MM, Liou GI: Retinal microglial activation and inflammation induced by Amadori-glycated albumin in a rat model of diabetes. Diabetes 2011;60:1122–1133.
- Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF: Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010;9:66.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(suppl 1):S5–S20.
- Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O’Brien PC, Melton LJ 3rd: The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care 1997;20:198–201.
- Zhu ZB, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, Shen WF: Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. Cardiology 2009;112:191–199.
- Kohzuma T, Koga M: Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus. Mol Diagn Ther 2010;14:49–51.
- Cockcroft DW, Gault HM: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
Guimarães J, Bastos M, Melo M, Carvalheiro M: Diabetic nephropathy: glomerular filtration rate and estimated creatinine clearance. Acta Med Port 2007;20:145–150.
- Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–811.
- Scanlon PJ, Faxon DP, Audet AM: ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999;33:1756–1824.
- Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, Cardona CY, Andries L, Peacock TP, Sabio H, Byers JR, Russell GB, Bleyer AJ: Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010;30:72–79.
- Rendell M, Paulsen R, Eastberg S, Stephen PM, Valentine JL, Smith CH, Nierenberg J, Rasbold K, Klenk D, Smith PK: Clinical use and time relationship of changes in affinity measurement of glycosylated albumin and glycosylated hemoglobin. Am J Med Sci 1986;292:11–14.
- Koga M, Kasayama S: Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57:751–762.
- Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y: Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007;54:139–144.
- Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y, Osaka CKD Expert Research Group: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896–903.
- Lee BW, Ihm J, Kang JG, Choi MG, Yoo HJ, Ihm SH: Amadori-glycated albumin-induced vascular smooth muscle cell proliferation and expression of inhibitor of apoptosis protein-1 and nerve growth factor-gamma. Biofactors 2007;31:145–153.
- Cohen MP, Shea E, Chen S, Shearman CW: Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003;141:242–249.
- Hattori Y, Banba N, Gross SS, Kasai K: Glycated serum albumin-induced nitric oxide production in vascular smooth muscle cells by nuclear factor kappaB-dependent transcriptional activation of inducible nitric oxide synthase. Biochem Biophys Res Commun 1999;1:128–132.
- Amore A, Cirina P, Conti G, Cerutti F, Bagheri N, Emancipator SN, Coppo R: Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004;19:53–60.
- Rodiño-Janeiro BK, González-Peteiro M, Ucieda-Somoza R, González-Juanatey JR, Alvarez E: Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev 2010;26:550–558.
- Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, Kollman C, Diabetes Research in Children Network (DirecNet) Study Group: The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 2011;12:690–695.
- De Caterina R, Zimarino M: Coronary artery remodelling in atherosclerosis: unfortunately unpredictable. Eur Heart J 2006;27:1761–1763.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.